NEXTBIOMEDICAL Co., Ltd.
Financials
Valuation Metrics
NEXTBIOMEDICAL Co., Ltd.'s Market Cap is ₩2355B. At end of 2025 it was ₩7400B. Ranked #739 of 2,410 in KR market (top 31%), #324 of 1,631 on KOSDAQ (top 20%), #22 of 94 in Health Care Equipment & Services (top 23%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 235.49B KRW | KR#739/2,410 Sec#22/94 |
| Revenue | 17.79B KRW | KR#2,168/2,410 Sec#72/94 |
| Net Income | 232.6M KRW | KR#1,534/2,410 Sec#49/94 |
| Total Assets | 59.27B KRW | KR#2,112/2,410 Sec#69/94 |
| Net Assets | 48.11B KRW | KR#1,930/2,410 Sec#61/94 |
| Employees | 72 | KR#1,857/2,410 Sec#74/94 |
| Value | ||
| P/E | 1012.59x | KR#1,546/2,410 Sec#49/94 |
| P/B | 4.90x | KR#2,250/2,410 Sec#87/94 |
| P/S | 13.24x | KR#2,303/2,410 Sec#86/94 |
| FCF Yield | -0.81% | KR—/2,410 Sec—/94 |
| Profitability | ||
| ROE | 0.48% | KR#1,516/2,410 Sec#49/94 |
| ROA | 0.39% | KR#1,498/2,410 Sec#49/94 |
| Op. Margin | -12.92% | KR#2,032/2,410 Sec#66/94 |
| Revenue Growth | 72.67% | KR#131/2,410 Sec#10/94 |
| Earnings Growth | -107.41% | KR#1,160/2,410 Sec#40/94 |
| Financial Health | ||
| Debt Ratio | 23.19% | KR#446/2,410 Sec#25/94 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/94 |
| FCF | -1.90B KRW | KR#1,330/2,410 Sec#41/94 |
| Cash | 6.79B KRW | KR#1,888/2,410 Sec#63/94 |
| Current Ratio | 5.02x | KR#283/2,410 Sec#24/94 |
| Performance | ||
| 1Y Return | -52.98% | KR#2,060/2,410 Sec#76/94 |
| 1M Return | -10.39% | KR#1,711/2,410 Sec#68/94 |
| From 52W High | -71.83% | KR#2,136/2,410 Sec#84/94 |
| 1Y MDD | -73.93% | KR#2,112/2,410 Sec#82/94 |
| Trading | ||
| Volume | 17,057 shares | KR#1,405/2,410 Sec#60/94 |
| Trading Value | 487.0M KRW | KR#692/2,410 Sec#20/94 |
| Foreign Own. | 2.20% | KR#1,551/2,410 Sec#56/94 |
| Per Share | ||
| EPS | 28 KRW | KR#1,532/2,410 Sec#49/94 |
| BPS | 5,812 KRW | KR#1,391/2,410 Sec#34/94 |
Company Info
Established in 2014, NEXT BIOMEDICAL is an innovative bio-solution company specially listed on the KOSDAQ market as a technology growth company in 2024. Leveraging polymer and drug delivery system technologies, the company develops products like hemostatic agents for endoscopy and vascular embolization microspheres, earning recognition for its technological prowess and innovation through FDA and CE certifications. It is pursuing the establishment of global distribution networks and sales channels by signing distribution rights agreements in the US, Europe, and Japan through partnerships with global medical device companies. NEXT BIOMEDICAL was established in 2014 and is headquartered in Yeonsu-gu, Incheon.